Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/1999
12/07/1999US5998469 Nervous system diosrders; autoimmune diseases; antiinflammatory agents
12/07/1999US5998465 Reduce tissue damage; antiinflammatory agents; oxidation resistance
12/07/1999US5998460 Phenylcarbamates of (-)-eseroline, (-)-N1-noreseroline and (-)-N1-benzylnoreseroline: selective inhibitors of acetyl and butyrylcholinesterase, pharmaceutical compositions and method of use thereof
12/07/1999US5998458 Administering inotropic agent and adrenergic receptor antagonist
12/07/1999US5998449 Malaria
12/07/1999US5998447 Heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
12/07/1999US5998443 Phosphorous containing benzothiophenes for treating estrogen deficiency
12/07/1999US5998425 Cytokine antagonist; antiarthritic agent
12/07/1999US5998411 Viricides
12/07/1999US5998405 Psychological disorders
12/07/1999US5998403 Salts of azelastine having improved solubility useful at providing a cytoprotective effect
12/07/1999US5998401 Naphthyl compounds, intermediates, compositions, and methods
12/07/1999US5998379 Serine protease inhibitors-proline analogs
12/07/1999US5998375 Treatment ov vasomotor disturbances such as hot flashes
12/07/1999US5998374 Clavaspirins
12/07/1999US5998372 Zinc ring protein
12/07/1999US5998370 Disorders caused by radiation therapy performed to treat diseases such as cancers and acquired immune deficiency syndrome (aids).
12/07/1999US5998367 Pramlintide acetate
12/07/1999US5998365 Solvent system comprising a hydrophilic component, a hydrophobic component, and a surfactant, wherein the hydrophilic component is propylene carbonate or polyethylene glycol having average molecular weight of less than 1000.
12/07/1999US5998364 Component B as cicatrizant
12/07/1999US5997867 Method of using humanized antibody against CD18
12/07/1999US5997865 Agonist antibodies against the flk2/flt3 receptor and uses thereof
12/07/1999US5997863 Attenuation of wound healing processes
12/07/1999US5997861 Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
12/07/1999CA2198231C Dihydropyridine derivatives as bradykinin antagonists
12/07/1999CA2180717C Use of phosphorus derivatives of alkaloids for treating endocrinopathies
12/07/1999CA2157410C Enhanced circulation effector composition and method
12/07/1999CA2140768C A method of increasing creatine supply depot
12/07/1999CA2015515C Pharmaceutical compositions containing antigen-antibody complexes and uses therefor
12/02/1999WO1999062315A2 Method for altering the activity of proteins of the pka signaling pathway
12/02/1999WO1999061645A1 Novel compound, wf00144
12/02/1999WO1999061626A2 Human hydrolase homologs: n-terminal asparagine amidohydrolase, glycosyl hydrolase, glucohydrolase, biotinidase, and n-acetylglucosamine 6-p deacetylase
12/02/1999WO1999061621A1 Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4
12/02/1999WO1999061617A1 Interleukins-21 and 22
12/02/1999WO1999061614A2 Human socs proteins
12/02/1999WO1999061611A1 Monomer protein with bone morphogenetic activity and medicinal agent containing the same for preventing and treating diseases of cartilage and bone
12/02/1999WO1999061609A1 Calmodulin related protein
12/02/1999WO1999061608A2 Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
12/02/1999WO1999061600A2 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
12/02/1999WO1999061593A1 USE OF MODIFIED LYSOZYME c TO PREPARE MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES
12/02/1999WO1999061590A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
12/02/1999WO1999061468A2 The induction of antibiotic peptides by lait (scd14) protein
12/02/1999WO1999061467A2 Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins
12/02/1999WO1999061466A1 Antiangiogenic drug to treat cancer, arthritis and retinopathy
12/02/1999WO1999061463A1 Novel secreted and membrane-associated proteins and uses therefor
12/02/1999WO1999061459A1 Alg-2lp, alg-2 like molecules and uses therefor
12/02/1999WO1999061446A1 G-csf mimetics
12/02/1999WO1999061445A1 G-csf mimetics
12/02/1999WO1999061444A2 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
12/02/1999WO1999061440A1 Novel substituted imidazole compounds
12/02/1999WO1999061437A1 Novel 2-alkyl substituted imidazole compounds
12/02/1999WO1999061436A1 Heterocyclic indole derivatives and mono- or diazaindole derivatives
12/02/1999WO1999061431A1 New dipeptidyl peptidase iv effectors
12/02/1999WO1999061424A1 Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
12/02/1999WO1999061423A1 New heterocyclically substituted amides, their production and their use
12/02/1999WO1999061422A1 Pyrrole substituted 2-indolinone protein kinase inhibitors
12/02/1999WO1999061421A1 A NOVEL VLA-4 INHIBITOR: oMePUPA-V
12/02/1999WO1999061418A2 1α-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF
12/02/1999WO1999061409A1 Bioreductive cytotoxic agents
12/02/1999WO1999061399A1 Genes encoding epsilon lycopene cyclase and method for producing bicyclic epsilon carotene
12/02/1999WO1999061097A2 Alpha emitting constructs and uses thereof
12/02/1999WO1999061051A1 Compositions and methods of modulating an immune response to an antigen
12/02/1999WO1999061036A1 Use of arabinoxylans for preparing a composition
12/02/1999WO1999061030A1 UTILIZATION OF 2-HYDROXY-4-TRIFLUOROMETHYLBENZOÏC ACID DERIVATIVES AS INHIBITORS OF THE ACTIVATION OF THE NUCLEAR TRANSCRIPTION FACTORS NF-λB
12/02/1999WO1999061027A1 Combination therapy for treatment of refractory depression
12/02/1999WO1999061025A1 Microemulsion preconcentrates containing a piperidine substance p antagonist
12/02/1999WO1999061020A1 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE
12/02/1999WO1999061019A1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
12/02/1999WO1999061013A2 COMPOUNDS HAVING IgE AFFECTING PROPERTIES
12/02/1999WO1999061010A2 Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
12/02/1999WO1999061008A2 Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals
12/02/1999WO1999060986A2 Apoptosis modulators that interact with the huntington's disease gene
12/02/1999WO1999060984A2 Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
12/02/1999WO1999050413A3 Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily
12/02/1999WO1999049871A8 Method of inhibiting membrane-type matrix metalloproteinase
12/02/1999WO1999047501A3 Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection
12/02/1999WO1999047173A3 Carrier for in vivo delivery of a therapeutic agent
12/02/1999WO1999044636A3 Il-12 enhancement of immune responses to t-independent antigens
12/02/1999WO1999043286A3 Isolated stromal cells for use in the treatment of diseases of the central nervous system
12/02/1999WO1999036064A3 Methods of treating tardive dyskinesia and other movement disorders
12/02/1999WO1999019354A9 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
12/02/1999DE19824470A1 Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen New Neurokininantagonisten, processes for their preparation containing these compounds and pharmaceutical compositions
12/02/1999DE19823831A1 Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen New pharmaceutical use of isoleucyl thiazolidide and its salts
12/02/1999CA2333320A1 Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound
12/02/1999CA2333270A1 1.alpha.-hydroxy-25-ene-vitamin d, analogs and uses thereof
12/02/1999CA2333159A1 Method
12/02/1999CA2333157A1 Novel substituted imidazole compounds
12/02/1999CA2333006A1 Calmodulin related protein
12/02/1999CA2332999A1 Compounds having ige affecting properties
12/02/1999CA2332989A1 Benzimidazole derivatives as modulators of ige
12/02/1999CA2332985A1 Benzimidazole analogs as down-regulators of ige
12/02/1999CA2332863A1 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor nf-.kappa.b
12/02/1999CA2332806A1 Bioreductive cytotoxic agents
12/02/1999CA2332772A1 Antiangiogenic drug to treat cancer, arthritis and retinopathy
12/02/1999CA2332617A1 Use of arabinoxylans for preparing a composition
12/02/1999CA2332402A1 Novel 2-alkyl substituted imidazole compounds
12/02/1999CA2332318A1 G-csf mimetics
12/02/1999CA2332317A1 G-csf mimetics
12/02/1999CA2329506A1 Alg-2lp, alg-2 like molecules and uses therefor
12/02/1999CA2329274A1 Interleukin-21
1 ... 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 ... 1564